Shut all madrasas in India; they promote terrorism: Shia leader tells PM

Mangaluru, May 31: The bus services by private operators in Dakshina Kannada and Udupi Districts will begin from tomorrow (June 1) with 15 per cent hike in the fares, Canara Bus Owners Association president Rajavarma Ballal said on Sunday.

In a statement issued here, he said that the members of the Association have appealed for a 3-month tax break. ''We have received tax breaks for 2 months and have demanded for an additional month again,'' he added.

He said that the government has agreed to a 15 per cent hike in bus fares. All the passes issued already will be converted into cash cards and no discounts will be available till the end of the COVID-19 crisis.

An added attraction in private buses will be the option of paying travel fares through smart cards.

According to Dakshina Kannada Bus Operators Association president Dilraj Alva, 50 per cent of 325 private city buses will resume their services on Monday. It also meant that 50 per cent of buses will operate on the allotted routes.

The smart cards (or travel cards called Chalo Card) will not be introduced on all routes at a time. They will be introduced in a phased manner covering all routes from Monday.

Mangaluru, Apr 25: The Kasturba medical college hospital at Manipal in Udupi district has decided to resume normal outpatient department services for all specialities from Monday.

In a release, hospital medical superintendent Avinash Shetty said the services will be made available from 8.30 am to 1 pm.

The services had been suspended in view of the nationwide lockdown.

Those visiting the hospital should visit the temporary screening kiosk set up outside the hospital, from where they will be shifted to the respective departments.

Mask is essential for all patients and their attenders.

Only one attender is allowed along with a patient.

Doctor's consultation through telemedicine service is also available from 9 am to 4 pm.

Trauma and emergency services will function as usual, the release said.

Bengaluru, Mar 27: Oncologist Dr. Vishal Rao, HCG Hospital Bengaluru on Friday said that human body cells release interferon chemical to kill viruses but it cannot be released by cells in the case of COVID-19 cases, leading to weak immune system. However, a therapy of specific concoction could be useful in treating COVID-19 patients.

"We got hold of some preprint suggesting that interferon is effective in COVID19," said Rao.

Speaking to news agency, he continued saying "When we withdraw blood for regular check-ups, we get buffy coat which can be used to take out cells and form interferon. These two chemicals and some other cytokines, in a specific concoction, could be potentially very useful in treating COVID-19 patients."

Rao said that they have built a concoction of cytokines which can be injected to reactivate immune system in COVID-19 patients.

"We are in a very initial stage and hope to be ready with its first set by this weekend. We have applied to the governement for an expedited review. We have also presented this before the state government" said Rao.

"We have a team of infection specialist, ICU team and other...all of us have worked together to build something that we believe. We want to serve the society at this hour of need," he added.

Dr Rao clarified that this is not a vaccine and this particular interferon therapy does not help to prevent the infection of COVID-19. However, this is focused and targeted towards COVID-19 positive patients or those who have just incubated the virus.

"We believe that in early stages as well as the patients who have just incubated, this particular therapy of interferon gama and other concoction of cytokines could be an effective method. In the late stages we are looking at specific dosage of the cells which are our own body cells which can actually be affective and could also be of use for the ventilator patients," he added.

Meanwhile, Dr Gururaj, Immunologist and Scientist told ANI that they are trying to cover two aspects, one is the early stage patients where they are trying to improve their immune systems.

"As Dr Vishal said, we are trying to see whether we can use the cytokines from our own immune cells which is a natural process but it is hampered in infected patients," said Dr Gururaj.

"In the last phase we are using cells which are used from the bone marrow of the patient or donors. We can use those cells to reduce the inflation and so called cytokines release syndrome which is basically the inflammatory response of the body," he added.